We are financed by world class investors
We are ambitious – The OMass pipeline is weighted towards programs addressing homogeneous, specialty care patient populations aligned with our intent to build integrated development and commercialization capabilities. Our pipeline also includes targets addressing large indications where OMass expects to partner in order to realize the full value of our programs.
Supportive and experienced investors – Originally a spinout from Oxford University, OMass is backed by a top-tier investor syndicate.
Syncona's purpose is to invest to extend and enhance human life. Syncona does this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.
Oxford Science Enterprises is a science business builder. They build world-changing businesses, bringing Oxford science to the world faster.
GV provides venture capital funding to bold new companies. Across the fields of life science, enterprise technology, consumer products and services, and frontier technology, GV's portfolio companies aim to improve lives and transform industries.
Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has consistently been named one of the most active lead life science investors in venture industry rankings. It is deeply engaged in the academic ecosystem, having founded The Laboratory for Bioengineering Research and Innovation at Harvard’s Wyss Institute; launched the MIT-Northpond Program - Advancing Life Science & Engineering Innovation; and sponsored a prize for women entrepreneurs at MIT. It has led or co-led over 60 financings over the past several years and sits on the board of the vast majority of these businesses. Learn more at npv.vc.
Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi.
